When all is said and done, it will depend on the announcement of a partnership or licensing agreement coupled with positive clinical data, the presentations and meet and greets are just levers in the system to improve awareness and promote the company profile, they have to keep this background work going until they have an announcement which the market will view favourably with a (hopefully) significant increase in SP, the rest is promotional white noise
Ann: December 2022 Quarterly Update and Appendix 4C, page-8
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.001(2.44%) |
Mkt cap ! $32.21M | |||
| Open | High | Low | Value | Volume |
| 4.2¢ | 4.2¢ | 4.0¢ | $43.30K | 1.062M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1110555 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 60000 | 1 |
View Market Depth
| Last trade - 14.47pm 04/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |